Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference

Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as antibodies that "bridge the gap" between immune T-cells and cancer cells by binding both